Results 11 to 20 of about 6,510 (202)

Drug-related problems and challenges encountered by pharmacists in nirmatrelvir/ritonavir counselling during the covid-19 pandemic: a multi-center study [PDF]

Scientific Reports
Pharmacists’ counselling roles expanded significantly during the COVID-19 pandemic, yet drug-related problems (DRPs) and challenges during nirmatrelvir/ritonavir counselling remain underreported.
Shamala Balan, Kavidha Mohan, Vanitha Hong Wee Liang, Hanis Hazwanie Ghazali, Chew Li Suan, Chong Chia Chee, Kong Wei En, Leana Fatimah Makhdzir, Nurul Syafiqah Samsuri, Nor Mazni Mohamad Tamyes, Juliana Nazlim Lim, Nur Amirah Mohd Noor Azami, Suhaili Samad, Kiren Kaur Chut Singh, Nurfareeza Nazir Khan, Siti Hajar Chamati, Nurdiana Hassan, Kuay Hue Ping, Farraha Nordin, Lau Wai Hoong, Azlen Awatif Abu Bakar   +20 more
doaj   +2 more sources

Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID‐19 [PDF]

Immunity, Inflammation and Disease
Background and Aim Simnotrelvir/ritonavir and nirmatrelvir/ritonavir are major treatments for COVID‐19, but their comparative efficacy and safety, especially in patients with moderate to severe COVID‐19, remain unclear.
Xin Chen, Xiao‐Qing Lin, Fang Cheng, Shi‐Lin Zheng, Qiang Zhang, Te Wu, Xian‐Gao Jiang, Ji‐Chan Shi   +7 more
doaj   +2 more sources

Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19 [PDF]

BMC Infectious Diseases
Purpose To compare the effectiveness and safety of two antiviral drugs, azvudine and nirmatrelvir/ritonavir, in treating hospitalized patients with COVID-19.
Jin Yang, Jiao Min, Ling Ding, Rong Liu, Ya Yang, Jian-feng Zhang, Wei Lei   +6 more
doaj   +2 more sources

Risk of acute liver injury following the nirmatrelvir/ritonavir use [PDF]

, 2023
Background: Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were reported as adverse events of nirmatrelvir/ritonavir users in the EPIC-HR trial.Aim: To quantify the risk and severity of acute liver injury (ALI ...
Au, Ivan Chi Ho, Cheng, Wing Yiu, Cowling, Benjamin J, Lau, Eric Ho Yin, Lau, Kristy Tsz Kwan, Leung, Gabriel M, Mak, Lung Yi, So, Ching Hei, Wong, Carlos King Ho, Yuen, Man Fung   +9 more
core   +1 more source

High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients [PDF]

, 2023
Objectives: Immunocompromised patients have an increased risk of severe or prolonged COVID-19. Currently available drugs are registered to treat COVID-19 during the first 5 to 7 days after symptom onset.
Bogers, Susanne, Franken, Bas, Geurts van kessel, Corine H., Gharbharan, Arvind, Huygens, Sammy, Oude Munnink, Bas B., Rijnders, Bart J.A., Serroukh, Yasmina, Snoek, Britt, Van Hagen, P. Martin   +9 more
core   +2 more sources

MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY [PDF]

, 2023
Introduction: Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression to severe SARS-CoV-2 infections, which reduce both hospitalization and mortality rates.
Adžić-Vukičević, Tatjana, Arellano, Elena, Bavastro, Martina, Besson, Caroline, Biernat, Monika M, Blennow, Ola, Buquicchio, Caterina, Calbacho, María, Cattaneo, Chiara, Cordoba, Raul, Cornely, Oliver A, Criscuolo, Mariana, Dargenio, Michelina, Del Principe, Maria Ilaria, Delia, Mario, Dávila-Valls, Julio, Erben, Nurettin, Espigado, Ildefonso, Falces-Romero, Iker, Farina, Francesca, Fouquet, Guillemette, Fracchiolla, Nicola S, García-Bordallo, Daniel, Gavriilaki, Eleni, Glenthøj, Andreas, Gräfe, Stefanie, Hernández-Rivas, José-Ángel, Hersby, Ditte Stampe, Itri, Federico, Koehler, Philipp, Kohn, Milena, Labrador, Jorge, Lavilla-Rubira, Esperanza, Limongelli, Alessandro, López-García, Alberto, Marchesi, Francesco, Marchetti, Monia, Martín-Pérez, Sonia, Meers, Stef, MelisÇOLAK, Gökçe, Merelli, Maria, Mitrovic, Mirjana, Mišković, Bojana, Mladenović, Miloš, Nordlander, Anna, Pagano, Livio, Pantic, Nikola, Petzer, Verena, Praet, Jens VAN, Prezioso, Lucia, Rahimli, Laman, Romano, Alessandra, Salmanton-García, Jon, Schönlein, Martin, Sili, Uluhan, Tascini, Carlo, Tragiannidis, Athanasios, Vena, Antonio, Weinbergerová, Barbora, Wolf, Dominik, Čolović, Natasa   +60 more
core   +3 more sources

Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients – a case series with four patients

BMC Nephrology, 2023
Background Despite vaccination coronavirus disease 2019 (COVID-19)-associated mortality caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains high in kidney transplant recipients.
Johanna Schneider, Rika Wobser, Wolfgang Kühn, Dirk Wagner, Yakup Tanriver, Gerd Walz   +5 more
doaj   +1 more source

NIRMATRELVIR/RITONAVIR (NIRI) EM PACIENTES COM COVID-19 E MALIGNIDADES HEMATOLÓGICAS: RELATO DO EPICOVIDEHA (REGISTRO INTERNACIONAL ONLINE DE PACIENTES COM MALIGNIDADES HEMATOLÓGICAS, INFECTADOS POR SARS-COV-2)

Brazilian Journal of Infectious Diseases, 2023
Introdução: O tratamento com NIRI diminui a taxa de hospitalização em pacientes imunocompetentes com COVID-19, mas os dados sobre a eficácia em pacientes com malignidade hematológica (MH) são escassos.
Jon Salmanton-García, Francesco Marchesi, Livio Pagano, Oliver A. Cornely   +3 more
doaj   +1 more source

Severe COVID-19 following Rituximab and Nirmatrelvir/ritonavir treatment in a patient with MCTD, Case Report [PDF]

, 2023
This is an article about how the use of medications such as nirmatrelvir/ritonavir can cause rebound COVID-19 and how the use of Rituximab, a biologic agent, can prolong the duration and increase severity of symptoms of COVID-19 in patients with pre ...
Baig, Rohail A, Chowdhury, Faieja, Dakwale, Pranjali, Mehta, Varun, Sheikh, Adnaan, Siddiqui, Omar   +5 more
core   +2 more sources

Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS

Разработка и регистрация лекарственных средств, 2023
Introduction. SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) is expected to remain a persistent global threat. Therefore, development of coronavirus disease 2019 (COVID-19) drugs is the most urgent global issue.
T. N. Komarov, P. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, N. S. Bagaeva, I. E. Shohin, K. Ya. Zaslavskaya, P. A. Bely   +7 more
doaj   +1 more source